Publications

5600 Results

Orteronel for metastatic hormone sensitive prostate cancer: A multicenter, randomized, open-label phase III trial (SWOG-1216)

Authors
N Agarwal;C Tangen;M Hussain;S Gupta;M Plets;P Lara;A Harzstark;P Twardowski;C Paller;D Zylla;M Zibelman;E Levine;B Roth;A Goldkorn;D Vaena;M Kohli;A Crispino;N Vogelzang;IM Thompson;DI Quinn
Journal / Conference
Journal of Clinical Oncology Oct 1;40(28):3301-3309
Year
2022
Research Committee(s)
Genitourinary
PMID
PMID35446628
PMC
PMC9553390
Study Number(s)
S1216

A More Efficient Approach to Clinical Trial Data Collection: The SWOG-nCartes Pilot Collaboration

Authors
C Cook;D Weatherbee;A Smith;S Yadav;G Bhardwaj;J Mcllwain;A Hoering;M LeBlanc;K Goodman
Journal / Conference
Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster
Year
2022
Research Committee(s)
Multiple sites

Lessons from Implementing Practice-Level Cluster Randomized Studies within the NCORP Setting

Authors
K Arnold;G Anderson;D Weatherbee
Journal / Conference
Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster
Year
2022
Research Committee(s)
Cancer Care Delivery, Prevention, Screening, and and Surveillance
Study Number(s)
S1415CD, S1904, S2108CD

A non-factorial analysis of a factorial Phase II trial design to evaluate single agent and combination consolidation therapies following CD19 CAR T-cell therapy for relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL): SWOG-S2114

Authors
H Li;M LeBlanc;B Hess;N Hossain;SM Smith;P Stiff;J Friedberg
Journal / Conference
Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster
Year
2022
Research Committee(s)
Lymphoma
Study Number(s)
S2114

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer

Authors
S Schild;X Wang;C Bestvina;T Williams;G Masters;A Singh;T Stinchcombe;J Salama;S Wolf;T Zemla;N Duma;S Chun;A Amini;D Kozono;C Watt
Journal / Conference
Clinical Lung Cancer Jul;23(5):e317-e320
Year
2022
Research Committee(s)
Lung
PMID
PMID35613998
PMC
PMC9634857
Study Number(s)
A082002

Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)

Authors
P Mack;J Miao;M Redman;J Moon;S Goldberg;R Herbst;M Melnick;Z Walther;F Hirsch;K Politi;K Kelly;D Gandara
Journal / Conference
Clinical Cancer Research Sep 1;28(17):3752-3760
Year
2022
Research Committee(s)
Lung
PMID
PMID35713632
PMC
PMC9444942
Study Number(s)
S1403

Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes [Editorial]

Authors
T Leal;S Dahlberg;S Ramalingam
Journal / Conference
Journal of Clinical Oncology Jul;23(5):e317-e320
Year
2022
Research Committee(s)
Lung
PMID
PMID35658027
Study Number(s)
S1400, S1800A

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial

Authors
P Goodwin;B Chen;K Gelmon;T Whelan;M Ennis;J Lemieux;J Ligibel;D Hershman;I Mayer;T Hobday;J Bliss;P Rastogi;M Rabaglio-Poretti;S Mukherjee;J Mackey;V Abramson;C Oja;R Wesolowski;A Thompson;D Rea;P Stos;L Shepherd;V Stambolic;W Parulekar
Journal / Conference
JAMA May 24;327(20):1963-1973
Year
2022
Research Committee(s)
Breast
PMID
PMID35608580
PMC
PMC9131745

Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A

Authors
L Korde;M Somerfield;D Hershman
Journal / Conference
JCO Oncology Practice May 20;40(15):1696-1698
Year
2022
Research Committee(s)
Breast
PMID
PMID35417251

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Authors
L Muffly;J Yin;S Jacobson;A Wall;E Quiroz;A Advani;S Luger;M Tallman;M Litzow;M Foster;F Appelbaum;H Erba;R Larson;T Keegan;W Stock
Journal / Conference
Blood Advances Jul 26;6(14):4085-4092
Year
2022
Research Committee(s)
Leukemia
PMID
PMID35838753
Study Number(s)
C10403